SCHEMBL24027894

SCHEMBL24027894

CC(=O)/C(=N/O)C(=O)Nc1cccc(C2(C(F)(F)F)CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 2/20 0.40
▸ MAPT P10636 4/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KCNJ6 P48051 1/20 0.36
▸ KCNJ5 P48544 1/20 0.36
▸ KCNJ3 P48549 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ BACE1 P56817 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ GPR35 Q9HC97 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30255658 0.79 LMNA (0.46) GFERMAPTLMNAGAAMEN1
SCHEMBL24027845 0.79 LMNA (0.46) GFERMAPTLMNAGAAMEN1
SCHEMBL24028391 0.78 ALDH1A1 (0.58) MAPTL3MBTL1LMNAGAAMEN1
SCHEMBL24027994 0.78 ALDH1A1 (0.58) MAPTL3MBTL1LMNAGAAMEN1
SCHEMBL29409971 0.77 ALDH1A1 (0.47) GFERMAPTL3MBTL1LMNAGAA
SCHEMBL22678605 0.77 ALDH1A1 (0.47) GFERMAPTL3MBTL1LMNAGAA
SCHEMBL24028223 0.77 KMT2A (0.48) MAPTL3MBTL1LMNAGAAMEN1
SCHEMBL24028205 0.76 ACHE (0.47) GFERMAPTL3MBTL1MEN1KMT2A
SCHEMBL24028204 0.75 PDK1 (0.42) GFERMAPTL3MBTL1GAAMEN1
SCHEMBL24028135 0.75 ALDH1A1 (0.43) GFERMAPTLMNAGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 — — US disclosed
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 — — US disclosed
CN-115697974-A Imidazole 3-oxide derivative based ACSS2 inhibitors and methods of use thereof 美特波米德有限公司 2023-02-03 — — CN disclosed
WO-2021229571-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2021-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 GFER 2130/4885MAPT 2167/4885L3MBTL1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback